Results 181 to 190 of about 1,264,950 (306)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies. [PDF]

Immunotherapy
Li Z, Mahmood I.
europepmc   +1 more source

Rubella virus-associated chronic inflammation in primary immunodeficiency diseases. [PDF]

Curr Opin Allergy Clin Immunol, 2020
Perelygina L, Icenogle J, Sullivan KE.
europepmc   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study. [PDF]

Allergy Asthma Clin Immunol
Čižnár P, Roderick M, Schneiderova H, Jeseňák M, Kriván G, Brodszki N, Jolles S, Atisso C, Fielhauer K, Saeed-Khawaja S, McCoy B, Yel L.   +11 more
europepmc   +1 more source

Molecular Mechanisms of Leukocyte Migration and Its Potential Targeting-Lessons Learned From MKL1/SRF-Related Primary Immunodeficiency Diseases. [PDF]

Front Immunol, 2021
Sprenkeler EGG, Guenther C, Faisal I, Kuijpers TW, Fagerholm SC.   +4 more
europepmc   +1 more source

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

British Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé, Juliette A. van den Noort, Iva Lelios, Diana R. Pereira, Marzia A. Scelsi, Erica S. Klaassen, Philipp Schoenenberger, Naomi B. Klarenbeek, Pierre‐Eric Juif, Pascal Espie, Manon A. A. Jansen, Matthijs Moerland, Richard W. D. Welford   +12 more
wiley   +1 more source

Mechanism and target treatment of primary immunodeficiency diseases with systemic lupus erythematosus-like phenotype. [PDF]

Pediatr Discov
Liu S, Zhang Z, Tang X, Zhao X, An Y.
europepmc   +1 more source

Clinical Features That Identify Children With Primary Immunodeficiency Diseases

BACKGROUND: The 10 warning signs of primary immunodeficiency diseases (PID) have been promoted by various organizations in Europe and the United States to predict PID. However, the ability of these warning signs to identify children with PID has not been
Gennery AR, Hughes SM, Colarusso G, Subbarayan A, Slatter M, Cant AJ, Arkwright PD   +6 more
core